These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 36506039)

  • 1. Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis.
    Sonawane K; Castellano T; Washington C; Ting J; Surinach A; Kirshner C; Chhatwal J; Ayer T; Moore K
    Gynecol Oncol Rep; 2022 Dec; 44(Suppl 1):101101. PubMed ID: 36506039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis.
    Sonawane K; Castellano T; Washington C; Ting J; Surinach A; Kirshner C; Chhatwal J; Ayer T; Moore K
    Gynecol Oncol Rep; 2022 Dec; 44():101121. PubMed ID: 36589508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of care and health care resource use among Medicaid-enrolled women with recurrent or metastatic cervical cancer.
    Leath CA; Nysenbaum J; Ting J; Zhang YJ; Fiori A; Pauly N
    J Manag Care Spec Pharm; 2023 May; 29(5):490-498. PubMed ID: 37121257
    [No Abstract]   [Full Text] [Related]  

  • 4. Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy.
    Johnston S; Wilson K; Varker H; Malangone-Monaco E; Juneau P; Riehle E; Satram-Hoang S; Sommer N; Ogale S
    Clin Colorectal Cancer; 2017 Dec; 16(4):386-396.e1. PubMed ID: 28619608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: A community oncology-based analysis.
    Alholm Z; Monk BJ; Ting J; Pulgar S; Boyd M; Sudharshan L; Bains S; Nicacio L; Coleman RL
    Gynecol Oncol; 2021 May; 161(2):422-428. PubMed ID: 33741208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany.
    Niegisch G; Gerullis H; Lin SW; Pavlova J; Gondos A; Rudolph A; Haas G; Hennies N; Kramer MW
    J Cancer; 2018; 9(8):1337-1348. PubMed ID: 29721042
    [No Abstract]   [Full Text] [Related]  

  • 7. Trends in treatment patterns and costs of care among patients with advanced stage cervical cancer.
    Musa FB; Brouwer E; Ting J; Schwartz NRM; Surinach A; Bloudek L; Ramsey SD
    Gynecol Oncol; 2022 Mar; 164(3):645-650. PubMed ID: 35031189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Patterns and Economic Burden by Lines of Therapy Among Patients with Advanced Hepatocellular Carcinoma Treated with Systemic Cancer Therapy.
    Bonafede MM; Korytowsky B; Singh P; Cai Q; Cappell K; Jariwala-Parikh K; Sill B; Parikh ND
    J Gastrointest Cancer; 2020 Mar; 51(1):217-226. PubMed ID: 31011982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States.
    Galsky MD; Pal SK; Lin SW; Ogale S; Zivkovic M; Simpson J; Derleth C; Schiff C; Sonpavde G
    Bladder Cancer; 2018 Apr; 4(2):227-238. PubMed ID: 29732393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Treatment Patterns and Outcomes Among Patients with Basal Cell Carcinoma Following First-Line Hedgehog Inhibitor Discontinuation.
    Cowey L; Chen CI; Aguilar KM; Davies K; LaFontaine PR; Fury MG; Bowler T; Golozar A; Jalbert JJ
    Dermatol Ther (Heidelb); 2022 May; 12(5):1211-1224. PubMed ID: 35507216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States.
    Seiter K; Latremouille-Viau D; Guerin A; Ndife B; Habucky K; Tang DH; Pivneva I; Gagnon-Sanschagrin P; Joseph GJ
    Adv Ther; 2018 Oct; 35(10):1671-1685. PubMed ID: 30155792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study.
    Wells JC; Dudani S; Gan CL; Stukalin I; Azad AA; Liow E; Donskov F; Yuasa T; Pal SK; De Velasco G; Hansen AR; Beuselinck B; Kollmannsberger CK; Powles T; McGregor BA; Duh MS; Huynh L; Heng DYC
    Clin Genitourin Cancer; 2021 Aug; 19(4):354-361. PubMed ID: 33863648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies.
    Purdum A; Tieu R; Reddy SR; Broder MS
    Oncologist; 2019 Sep; 24(9):1229-1236. PubMed ID: 30850561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Treatment Patterns and Economic Burden Following First-Line Trastuzumab in Patients with Metastatic Gastric Cancer in the USA.
    Barzi A; Lin F; Song J; Lam C; Nie X; Noman A; Kwong WJ
    Drugs Real World Outcomes; 2023 Sep; 10(3):395-404. PubMed ID: 37540381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to progression after first-line tyrosine kinase inhibitor predicts survival in patients with metastatic renal cell carcinoma receiving second-line molecular-targeted therapy.
    Ishihara H; Kondo T; Yoshida K; Omae K; Takagi T; Iizuka J; Tanabe K
    Urol Oncol; 2017 Sep; 35(9):542.e1-542.e9. PubMed ID: 28619633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study.
    Shore ND; Ionescu-Ittu R; Laliberté F; Yang L; Lejeune D; Yu L; Duh MS; Mahendran M; Kim J; Ghate SR
    Clin Genitourin Cancer; 2021 Dec; 19(6):480-490. PubMed ID: 34373223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma.
    De Velasco G; Xie W; Donskov F; Albiges L; Beuselinck B; Srinivas S; Agarwal N; Lee JL; Brugarolas J; Wood LA; Rha SY; Kollmannsberger C; North S; Kanesvaran R; Rini BI; Broom R; Yamamoto H; Kaymakcalan MD; Heng DYC; Choueiri TK
    Clin Genitourin Cancer; 2017 Jun; 15(3):403-410.e2. PubMed ID: 28254206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer.
    Le DT; Ott PA; Korytowsky B; Le H; Le TK; Zhang Y; Maglinte GA; Abraham P; Patel D; Shangguan T; Chau I
    Clin Colorectal Cancer; 2020 Mar; 19(1):32-38.e3. PubMed ID: 31813769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Patterns in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: Analysis of US Insurance Claims Databases.
    Soo RA; Seto T; Gray JE; Thiel E; Taylor A; Sawyer W; Karimi P; Marchlewicz E; Brouillette M
    Drugs Real World Outcomes; 2022 Mar; 9(1):31-41. PubMed ID: 34510401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data.
    Nieva J; Reckamp KL; Potter D; Taylor A; Sun P
    Drugs Real World Outcomes; 2022 Sep; 9(3):333-345. PubMed ID: 35661118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.